Research programme: chimeric antigen receptor T-cell therapeutics - AbbVie/Caribou Biosciences
Alternative Names: CAR-T cell therapeutics - AbbVie/Caribou BiosciencesLatest Information Update: 06 Oct 2023
At a glance
- Originator AbbVie
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 26 Sep 2023 Abbvie terminates its research and development agreement with Caribou Biosciences for chimeric anigen receptor T-cell therapeutics
- 01 Mar 2022 Caribou Biosciences has patent protection for next-generation CRISPR genome editing technology worldwide
- 01 Mar 2022 Caribou Biosciences has patents pending for next-generation CRISPR genome editing technology worldwide